CA3179671A1 - Kinase inhibitors and uses thereof - Google Patents
Kinase inhibitors and uses thereofInfo
- Publication number
- CA3179671A1 CA3179671A1 CA3179671A CA3179671A CA3179671A1 CA 3179671 A1 CA3179671 A1 CA 3179671A1 CA 3179671 A CA3179671 A CA 3179671A CA 3179671 A CA3179671 A CA 3179671A CA 3179671 A1 CA3179671 A1 CA 3179671A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- alkyl
- compound
- heterocyclyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063113P | 2020-08-07 | 2020-08-07 | |
| US63/063,113 | 2020-08-07 | ||
| PCT/US2021/044907 WO2022032071A1 (en) | 2020-08-07 | 2021-08-06 | Kinase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3179671A1 true CA3179671A1 (en) | 2022-02-10 |
Family
ID=77711412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3179671A Pending CA3179671A1 (en) | 2020-08-07 | 2021-08-06 | Kinase inhibitors and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230303570A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192582A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023538521A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230112605A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116710453A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021321536A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023002248A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179671A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001312A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022032071A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120129682A (zh) * | 2022-08-25 | 2025-06-10 | 英莱汶公司 | 用于抑制raf激酶的萘啶化合物 |
| WO2024199388A1 (zh) * | 2023-03-29 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
| WO2025064567A1 (en) * | 2023-09-19 | 2025-03-27 | Enliven Inc. | Tricyclic phenols for inhibition of raf kinases |
| CN122555710A (zh) * | 2024-01-15 | 2026-08-11 | 上海瑛派药业有限公司 | Wee1抑制剂的晶型及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2310657C2 (ru) * | 2002-04-03 | 2007-11-20 | Ф.Хоффманн-Ля Рош Аг | Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их |
| EP2348020A1 (en) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Preparation process of erlotinib |
| FR2974088A1 (fr) * | 2011-04-12 | 2012-10-19 | Pf Medicament | Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux |
| CN109789143A (zh) * | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| CN110950867A (zh) * | 2018-09-27 | 2020-04-03 | 首药控股(北京)有限公司 | 一种fgfr4激酶抑制剂及其制备方法和用途 |
-
2021
- 2021-08-06 US US18/019,377 patent/US20230303570A1/en active Pending
- 2021-08-06 EP EP21769214.4A patent/EP4192582A1/en active Pending
- 2021-08-06 CA CA3179671A patent/CA3179671A1/en active Pending
- 2021-08-06 KR KR1020237007882A patent/KR20230112605A/ko active Pending
- 2021-08-06 BR BR112023002248A patent/BR112023002248A2/pt unknown
- 2021-08-06 WO PCT/US2021/044907 patent/WO2022032071A1/en not_active Ceased
- 2021-08-06 JP JP2023507887A patent/JP2023538521A/ja active Pending
- 2021-08-06 CN CN202180068725.2A patent/CN116710453A/zh active Pending
- 2021-08-06 MX MX2023001312A patent/MX2023001312A/es unknown
- 2021-08-06 AU AU2021321536A patent/AU2021321536A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001312A (es) | 2023-04-12 |
| BR112023002248A2 (pt) | 2023-03-07 |
| EP4192582A1 (en) | 2023-06-14 |
| AU2021321536A1 (en) | 2023-03-09 |
| KR20230112605A (ko) | 2023-07-27 |
| JP2023538521A (ja) | 2023-09-08 |
| CN116710453A (zh) | 2023-09-05 |
| US20230303570A1 (en) | 2023-09-28 |
| WO2022032071A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020343681B2 (en) | Heterocyclic RIP1 kinase inhibitors | |
| KR102001745B1 (ko) | 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물 | |
| KR102824962B1 (ko) | 헤테로시클릭 rip1 억제 화합물 | |
| ES2708211T3 (es) | 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas | |
| AU2022349569A1 (en) | Pyridine derivative and use thereof | |
| EP2855459B1 (en) | Aminoquinazoline and pyridopyrimidine derivatives | |
| KR102376354B1 (ko) | 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 phd의 저해제로서의 그의 용도 | |
| KR102609431B1 (ko) | Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체 | |
| US9556171B2 (en) | Certain protein kinase inhibitors | |
| JP2022526854A (ja) | ホスファチジルイノシトール3-キナーゼ阻害剤 | |
| CA3107365A1 (en) | Pyrazine compounds and uses thereof | |
| WO2019060611A1 (en) | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES | |
| US20230303570A1 (en) | Kinase inhibitors and uses thereof | |
| WO2013113669A1 (en) | Isoquinoline and naphthyridine derivatives | |
| JP2017526720A (ja) | キナーゼ阻害剤としての化合物および組成物 | |
| WO2023185073A1 (zh) | Parp7抑制剂及其用途 | |
| CA3185491A1 (en) | Atr inhibitors and uses thereof | |
| JP2019535790A (ja) | Gsk−3阻害剤 | |
| JP2024510306A (ja) | Ctla-4低分子分解剤及びその使用 | |
| WO2024173323A1 (en) | Amino-substituted pyrrolotriazine derivatives as inhibitors of sgk1 | |
| CN120513245A (zh) | 造血前驱细胞激酶1的吡啶酮及嘧啶酮抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220930 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240705 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250127 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250131 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250218 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250218 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250407 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250807 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250813 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250916 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250916 |